Category Archives: Regenerative Medicine

Antibe Therapeutics Inc. (OTCMKTS:ATBPF Get Rating) saw a large growth in short interest in April. As of April 15th, there was short interest totalling 46,100 shares, a growth of 45.9% from the March 31st total of 31,600 shares. Based on an average daily trading volume, of 12,500 shares, the short-interest ratio is presently 3.7 days.

ATBPF opened at $0.56 on Friday. Antibe Therapeutics has a one year low of $0.44 and a one year high of $3.70. The stocks fifty day moving average is $0.59 and its 200-day moving average is $0.60. The company has a market capitalization of $29.07 million, a PE ratio of -1.33 and a beta of 0.22.

Antibe Therapeutics (OTCMKTS:ATBPF Get Rating) last posted its quarterly earnings data on Monday, February 14th. The company reported ($0.08) EPS for the quarter, topping the Zacks consensus estimate of ($0.13) by $0.05. Antibe Therapeutics had a negative return on equity of 42.02% and a negative net margin of 244.59%. Research analysts expect that Antibe Therapeutics will post -0.33 earnings per share for the current fiscal year.

Antibe Therapeutics Inc, a biotechnology company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.

See Also

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Read the original:
Antibe Therapeutics Inc. (OTCMKTS:ATBPF) Short Interest Update - Defense World

FLYING IN: The National Restaurant Association this week is holding its first in-person fly-in since before the pandemic began, which comes at a crucial time for industry advocates as lawmakers try to rally support for a small-business Covid relief package that would send restaurants additional funding.

More than 500 industry advocates are set to hold 200 meetings with lawmakers of both parties in the House and Senate to push for passage of more pandemic assistance, as well as maintaining the industrys tip credit, progress on labor issues, and the reinstatement of a the Covid-era employee retention tax credit.

MORE FLY-INS: Restaurant advocates arent the only ones getting face time with lawmakers this week. Member companies of the Portland Cement Association, which represents the majority of U.S. cement producers, will be in Washington this week to lobby policymakers on policies to help the cement industry cut carbon emissions, especially with a construction boom expected as a result of the infrastructure bill.

The trade group will discuss its recently released Roadmap to Carbon Neutrality, which includes the expansion of a tax break to install carbon capture equipment, funding for the Energy Department for research and development of carbon capture technologies and more.

Tomorrow, FMI - The Food Industry Association will kick off its fly-in with business leaders and other representatives from the food retailer, wholesaler and supplier community hitting the Hill to discuss inflation and supply chain challenges stemming from the war in Ukraine, as well as workforce shortages.

Not all of the fly-ins scheduled for this week will be in person. The PKD Foundation is keeping virtual its annual event, which is set to kick off Wednesday. The foundation has more than 100 virtual meetings planned with members, including Sen. Mike Braun (R-Ind.), Reps. Mark Amodei (R-Nev.), Judy Chu (D-Calif.) Antonio Delgado (D-N.Y.), Mike Gallagher (R-Wis.), Brett Guthrie (R-Ky.), Donald Payne (D-N.J.) and Lloyd Smucker (R-Pa.), and dozens of other offices to call for more funding opportunities and legislation to benefit kidney disease patients.

Good afternoon and welcome to PI. Whats going on out there? Let me know: [emailprotected]. And be sure to follow me on Twitter: @caitlinoprysko.

JONES RETURNS TO ARENT FOX: Former Sen. Doug Jones has returned to ArentFox Schiff following his stint as the sherpa for incoming Supreme Court Justice Ketanji Brown Jacksons confirmation process. Jones and a top aide landed at the firm about a year ago, working with the firms government relations and government enforcement and white-collar groups as counsel.

Jones had taken a temporary leave of absence from the firm to oversee Jacksons confirmation, and now that hes returned will continue advising clients on a variety of public policy issues and legal matters, particularly in the National Security, Health Care, and Financial Services industries, ArentFox said in a statement.

NEW TWITTER OWNER NO STRANGER TO WASHINGTON BRAWLS: Elon Musk has publicly ridiculed the Securities and Exchange Commission, scrapped with federal airwaves and car-safety regulators and sued the Pentagon to gain access to military space contracts. But with his Twitter acquisition, the billionaire who founded Tesla and SpaceX has cast himself as a central player in Washingtons most contentious political battles a role that could bring him a whole new level of blowback, our Emily Birnbaum writes.

Emily and several other POLITICO policy reporters recount some of Musks most contentious clashes with the halls of power in Washington to game out how Musk might approach his new role as Twitters owner. In his new position helming the favorite social media network of politicians and political journalists, Musk will face a hotter spotlight than ever both giving him a position of power over the regulators hes criticized for years and putting himself in their line of fire, they write.

Musk has made a reputation for himself as a bombastic political player, unafraid to poke his finger in the eye of regulators. And hes likely to continue that approach at Twitter, where Congress could subject him to the same scrutiny targeted toward social media CEOs like Mark Zuckerberg.

PR FIRMS CONTINUE TO WAGE CAMPAIGNS ON BEHALF OF KREMLIN-TIED CLIENTS: Leonard Blavatnik, a Ukrainian-born businessman whose name graces Harvard Medical School and a part of Carnegie Hall, amassed his wealth, in part, from the privatization of oil and aluminum after the fall of the USSR. Over time, he worked alongside a number of oligarchs currently sanctioned by the EU or the U.S. for their ties to the government of Russian President Vladimir Putin, POLITICOs Hailey Fuchs reports.

But as Russia has launched a bloody and internationally condemned invasion of Ukraine, Blavatnik has gone to some lengths to ensure that his name isnt dragged into the matter, working through a public relations firm to make sure the press corps does not tie him to the Kremlin or describe him as an oligarch.

Blavatnik is one of several wealthy businessmen who have turned to public relations professionals to help navigate press coverage emanating from Russias assault on Ukraine. It has created a unique business opportunity for Madison Avenue and beyond.

Whereas K Street and some law firms have worked to distance themselves from Russian interests cutting connections with Kremlin-tied businesses PR professionals have stepped in to help illuminate the distinctions between those businessmen tied to Putin and those who want nothing to do with him, according to interviews and emails.

FIRST IN PI NATIVE AMERICAN GROUP ASKS CHAMBERS CLARK FOR SIT-DOWN: A Native American group that advocates for eliminating stereotypical Native American mascot caricatures and iconography while preserving culturally appropriate American Indian names, logos, and imagery in pop culture says it wants to meet with U.S. Chamber of Commerce President and CEO Suzanne Clark after Clark apologized for posting a photo last month standing beside two people in what appeared to be Native American headdresses.

We at NAGA, along with most American Indians, find Ms. Clarkes (sic) indiscriminate promotion of our sacred bonnet to be highly offensive, Native American Guardians Association board member Eunice Davidson Wicanhpiwastewin (Good Star Woman) said in a statement, adding that Clarks actions are inconsistent with many of the principles of the Chambers Fortune 500 members.

Tony Henson, another board member for the group, which has defended the Redskins name for the Washington football team, argued that while American Indians have overwhelmingly expressed their views that the use of powerful and beautiful native names and images in the public sphere are not offensive, the organization has an issue with the lack of Native Americans in the Chambers leadership ranks and what Henson called a complete lack of philanthropic support for American Indians.

We encourage Ms. Clarke and the U.S. Chamber of Commerce to meet with NAGAs leadership in order to discuss the steps its organization can take to promote the positive and inspiring culture of American Indians, he added.

A Chamber spokesperson said that Clark continues to stand by her apology last month in which she said she was deeply sorry for posting the photo. The spokesperson added that Clark would absolutely consider such a meeting when a request is made.

Maria Bowie is joining SMI as a vice president, where she will be registering to lobby. She was previously a director of government affairs at Leidos and is a Tom Cole and Ken Calvert alum.

Cristina Marcos has joined ROKK Solutions as a senior account director. She was most recently a congressional reporter at The Hill.

Evelyn Farkas will be the next executive director of the McCain Institute at Arizona State University. She was a deputy assistant secretary of Defense in the Obama administration and a congressional candidate in 2020.

Bullpen Strategy Group is promoting Christian Hertenstein to partner, promoting Michael Ahrens to senior vice president and adding Chris Martin as vice president in the communications practice. Martin most recently was deputy executive director of America Rising PAC.

Brownstein Hyatt Farber Schreck has hired Lauren Diekman as a senior policy adviser. She was most recently senior director of energy, infrastructure and environment at the Chambers U.S.-India Business Council.

Daniel Sepulveda is joining Platinum Advisors government relations team. He most recently was at Wiley, and is a former U.S. ambassador for telecommunications and media issues and a USTR and Senate alum.

Joe Hoellerer is now director of government affairs at the Information Technology Industry Council. He previously was senior manager of government relations at the Security Industry Association.

Craig Martell is joining DoD as chief digital and artificial intelligence officer. He most recently was head of machine learning for Lyft.

Jeann Lewis will be interim CEO of Faith in Public Life. She currently is vice chair of the board of directors, and works as vice president and chief engagement officer at the National Committee for Responsive Philanthropy. Lewis will replace the founding CEO, the Rev. Jennifer Butler, who will become founder in residence.

Maria Pica Karp will be vice president of global government relations at ADM. She previously spent 18 years at Chevron, including seven leading its global government affairs.

Alex Mitchell is now director of external relations for the Institute for the Study of War. He previously was vice president at Vox Global.

Wexton Victory Fund 2022 (Rep. Jennifer Wexton, Democratic Party of Virginia)

Build and Protect OK (Super PAC)MISSING VOICES. MISSING VOTES (Hybrid PAC)SAFEGUARDING OKLAHOMA VALUES PAC (Super PAC)

Alliance For Regenerative Medicine: Alliance For Regenerative MedicineArnold & Porter Kaye Scholer LLP: University Of RedlandsBecker & Poliakoff, P.A.: City Of Miami, FloridaBecker & Poliakoff, P.A.: Florida Gulf Coast University Foundation, Inc.Becker & Poliakoff, P.A.: Street Smarts VrCanyon Snow Consulting, LLC: Sanmina CorporationCarpi & Clay, Inc: Verity NowCavarocchi Ruscio Dennis Associates, L.L.C.: EcriContinental Strategy, LLC: Chamber Of Industry Of GuatemalaDla Piper LLP (US): Inter-Tribal Trade ConsortiumFederal Hall Policy Advisors, LLC: National Association Of Mutual Insurance CompaniesHogan Lovells US LLP: AigKing & Spalding LLP: Makana Therapeutics, Inc.Lne Group: Be Perfect FoundationLne Group: Conquer Paralysis NowLne Group: Hero One FoundationLne Group: Push To WalkMiller & Chevalier Chartered: One Town Square Consulting LLCMl Strategies, LLC: Northern Light HealthPaul V. Beddoe Government Affairs, LLC: Cencal HealthPrevail Communications, LLC: Forbes Tate Partners On Behalf Of Coalition For App FairnessSmith Dawson & Andrews: Fuentes Strategies, LLCSonosky, Chambers, Sachse, Endreson & Perry, LLP: Coeur D'Alene TribeThe Campbell Consulting Group: New Morning FoundationThe Ferguson Group: City Of Blaine, MnThe Roosevelt Group: Corning Optical Communications LLCVan Scoyoc Associates: Ohio UniversityWinn Strategies, LLC: Twinlogic Strategies On Behalf Of Nokia Of America CorporationWinn Strategies, LLC: Twinlogic Strategies On Behalf Of Siia

Armory Hill Advocates (Formerly Known As Rawlson Policy Group): Kpc Global ManagementCartwright & Riley, Inc.: Hemlock Court Holdings CorporationChristopher Heinz: American Petroleum InstituteEnvision Strategy, LLC: Boloro Global LimitedGrassroots Political Consulting LLC: Attwill Vascular Technologies Lp/Attwill Medical SolutionsMcallister & Quinn, LLC: Friends University

See original here:
Restaurants fly in with more pandemic aid up in the air - POLITICO

DUBLIN--(BUSINESS WIRE)--The "Global Collagen and Gelatin Market Report Size, Trends & Growth Opportunity, By Source, By Type, By Application, By Region and Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

A protein which serves as one of the main building blocks for bones, skin, hair, muscles, tendons, and ligaments is called as Collagen and it is mostly used as an easy-to-digest nutritional supplement. A colorless, brittle, and water-soluble substance is Gelatin and it has a high molecular weight. Also, it is a rich source of protein and it contains lysine, which helps strengthen the bones.

Market Drivers

Diabetes is an important target indication - it can increase the incidence & complexity of wounds such as ulcerations (leg or foot ulcers), infections, and surgical wounds, requiring treatments & incurring exorbitant medical expenses.

Nearly 25% of diabetics in the Unites States develop foot ulcers during their lifetime, while ~15% of the diabetic population suffers from diabetic foot ulcers.

The increase in prevalence of DFUs is expected to drive the demand for regenerative medicine products like grafts and matrices. Thus, fueling the global collagen and gelatin market growth.

Furthermore, the increase in awareness about the collagen & changing consumer preferences & lifestyles will accelerate the demand for Global Collagen and Gelatin Market.

Market Restraints

The availability of efficient & reliable substitute biomaterials, which can heal, repair, or regenerate injured or diseased tissues & organs, is likely to restrain the market growth.

Several biomaterials such as chitosan, cellulose, alginate, hyaluronic acid, polylactic acid (PLA), polyglycolic acid (PGA), and poly (lactic-co-glycolic acid) (PLGA) are used as alternatives for collagen & gelatin in regenerative medicine. Such substitutes may hinder the global collagen & gelatin market growth across the globe.

Market Segmentation

Collagen and Gelatin Market sis segmented into major 4 categories. Based on Source, the market is segmented into Bovine, Porcine, Marine and Others. Based on Type, the market is segmented into Collagen and Gelatin. Based on Application, the market is segmented into Orthopaedic, Wound Care, Cardiovascular and Others. Based on Region, the market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East.

Regional Analysis

The market in North America is projected to dominate the Collagen and Gelatin market due to the presence of key market players in the region coupled with the rising geriatric population. Also, expected to expand at a significant growth rate over the forecast period of 2021 to 2027 owing to the rising geriatric population.

Furthermore, European region is projected to be second largest market of Collagen and Gelatin globally owing to the rising demand in food processing industry.

Market Key Players

Some of the key players operating in Global Collagen and Gelatin Market are Royal DSM, Collplant Biotechnologies, Nitta Gelatin Inc., Geistlich Pharma AG, Synerheal Pharmaceuticals, Collagen Solutions PLC, Collagen Matrix, Inc., Gelita AG, PB Leiner, Smith & Nephew.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Collagen & Gelatin Market Outlook

4.1 Overview

4.2 Market Dynamics

4.2.1 Drivers

4.2.2 Restraints

4.2.3 Opportunities

4.3 Porters Five Force Model

4.4 Value Chain Analysis

5 Collagen & Gelatin Market, By Type

5.1 Y-o-Y Growth Comparison, By Type

5.2 Collagen & Gelatin Market Share Analysis, By Type

5.3 Collagen & Gelatin Market Size and Forecast, By Type

5.3.1 Collagen

5.3.2 Gelatin

6 Collagen & Gelatin Market, By Application

6.1 Y-o-Y Growth Comparison, By Application

6.2 Collagen & Gelatin Market Share Analysis, By Application

6.3 Collagen & Gelatin Market Size and Forecast, By Application

6.3.1 Orthopedic

6.3.2 Wound Care

6.3.3 Cardiovascular

6.3.4 Others

7 Collagen & Gelatin Market, By Source

7.1 Y-o-Y Growth Comparison, By Source

7.2 Collagen & Gelatin Market Share Analysis, By Source

7.3 Collagen & Gelatin Market Size and Forecast, By Source

7.3.1 Bovine

7.3.2 Porcine

7.3.3 Marine

7.3.4 Others

8 Collagen & Gelatin Market, By Region

8.1 Collagen & Gelatin Market Share Analysis, By Region

8.2 Collagen & Gelatin Market Share Analysis, By Region

8.3 Collagen & Gelatin Market Size and Forecast, By Region

9 North America Collagen & Gelatin Market Analysis and Forecast (2021-2027)

10 Europe Collagen & Gelatin Market Analysis and Forecast (2021-2027)

11 Asia Pacific Collagen & Gelatin Market Analysis and Forecast (2021-2027)

12 Latin America Collagen & Gelatin Market Analysis and Forecast (2021-2027)

13 Middle East Collagen & Gelatin Market Analysis and Forecast (2021-2027)

14 Competitive Analysis

14.1 Competition Dashboard

14.2 Market share Analysis of Top Vendors

14.3 Key Development Strategies

15 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/j4p9wz

Go here to see the original:
Global Collagen and Gelatin Market Report to 2027 - Size, Trends & Growth Opportunities - ResearchAndMarkets.com - Business Wire

Roger Sawhney, M.D. to serve as Chief Business Officer

CAMBRIDGE, Mass., April 29, 2022 /PRNewswire/ -- Omega Therapeutics (NASDAQ: OMGA) (Omega), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming platform, today announced the appointment of Joshua Reed as Chief Financial Officer, effective May 23, 2022. Roger Sawhney, M.D., Omega's Chief Financial Officer, will serve as Chief Business Officer.

"We are excited to welcome Joshua to our management team. We expect that Joshua's track record of success and diverse experience across many disciplines including finance and operations will be important factors in Omega's future success. This news follows a number of key hires that we have announced this year, providing Omega with a strong and talented senior leadership team with the experience needed to execute on the promise of our pipeline and platform," said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. "I am equally excited for Roger to be able to focus on our business development efforts as we look to accelerate the potential of our epigenomic programming platform to deliver transformative therapies to patients."

"I am thrilled to be joining an exciting company with an innovative platform and a strong leadership team with the potential to be impactful across a wide-range of diseases and conditions," said Mr. Reed. "I look forward to working closely with our Board of Directors, management team and our shareholders to continue advancing our science."

Mr. Reed most recently served as Chief Financial Officer of Aldeyra Therapeutics, where he was responsible for finance, business development, investor relations, compliance, human resources, and information technology. During his time at Aldeyra, Mr. Reed led multiple capital raises, oversaw the company's interactions with current and prospective investors and managed all aspects of the company's financial close, including quarterly and annual SEC filings. Before Aldeyra, Mr. Reed held a variety of finance roles of increasing responsibility at Bristol-Myers Squibb, most recently serving as Vice President and Head of Finance Operations for the United States and Puerto Rico. While at Bristol-Myers Squibb, Mr. Reed also led financial planning and analysis and worked on various acquisitions, divestitures, alliances, and collaboration agreements. Earlier in his career, Mr. Reed worked at JP Morgan Chase, Credit Suisse First Boston, and Chase Manhattan Bank. Mr. Reed received his Bachelor of Science in Finance from Rutgers University and his Master of Business Administration from the University of Michigan.

About Omega TherapeuticsOmega Therapeutics, founded by Flagship Pioneering, is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines. The company's OMEGA Epigenomic Programming platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. Using a suite of technologies, paired with Omega's process of systematic, rational, and integrative drug design, the deterministic OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega's modular and programmable mRNA epigenetic medicines, Omega Epigenomic Controllers, target specific epigenomic loci within insulated genomic domains, EpiZips, from amongst thousands of unique, mapped, and validated genome-wide DNA-sequences, with high specificity to durably tune single or multiple genes to treat and cure diseases through Precision Genomic Control. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.

For more information, visitomegatherapeutics.com, or follow us onTwitterandLinkedIn

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the potential of the OMEGA Epigenomic Programming platform, the company's intention to advance its programs into the clinic, and the continued growth and scale up of the company. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the novel technology on which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and subsequently obtaining regulatory approval, if at all; the substantial development and regulatory risks associated with epigenomic controller machines due to the novel and unprecedented nature of this new category of medicines; our limited operating history; the incurrence of significant losses and the fact that we expect to continue to incur significant additional losses for the foreseeable future; our need for substantial additional financing; our investments in research and development efforts that further enhance the OMEGA platform, and their impact on our results; uncertainty regarding preclinical development, especially for a new class of medicines such as epigenomic controllers; the fact that our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their regulatory development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences; the impact of increased demand for the manufacture of mRNA and LNP based vaccines to treat COVID-19 on our development plans; difficulties manufacturing the novel technology on which our OEC candidates are based; our ability to adapt to rapid and significant technological change; our reliance on third parties for the manufacture of materials; our ability to successfully acquire and establish our own manufacturing facilities and infrastructure; our reliance on a limited number of suppliers for lipid excipients used in our product candidates; our ability to advance our product candidates to clinical development; and our ability to obtain, maintain, enforce and adequately protect our intellectual property rights.These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form10-K for the period ended December 31, 2021and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Contacts

Media contact:Jason BracoLifeSci Communications646.751.4361 [emailprotected]

Investor contact: Kevin MurphyArgot Partners 212.600.1902 [emailprotected]

SOURCE Omega Therapeutics

Read the original here:
Omega Therapeutics Announces Appointment of Joshua Reed as Chief Financial Officer - PR Newswire

New technologies and procedures are often met with pushback initially.

Thomas Schuler, MD, founder and CEO of the Virginia Spine Institute in Reston, joined "Becker's ASC Review Podcast" to talk about how the adoption of interventional medicine could change in the near future.

Note: This is an edited excerpt. Listen to the full podcast episode here.

Question: Over the next five years, what do you think will be different in the physician practice landscape, and what do you think will be the same?

Dr. Thomas Schuler: When you look back over medicine at things that have stood the test of time, X-rays have been around over a hundred years, and yet they're still essential. If you break an arm, you get a cast put on it to get the bone to heal, and you use the body's own biology to heal. Casting has been around for over a hundred years.

What's really exciting about the future is we're using people's own biology to heal. What I mean is, we're using regenerative medicine to heal injured discs, injured ligaments and restore people back to function without surgery, using their own biology.

There's a lot of naysayers who feel regenerative medicine hasn't been proven, but we've been doing this for over a decade and seen unbelievable change in how we manage patients.

We don't want to do a five-level fusion to treat back pain, but we do regenerative medicine where we take their marrow, concentrate it down, inject it into their disc, and now they're back skiing and golfing and doing everything.

So I believe that over the next five to 10 years, the rest of the medical community will finally wake up and understand what an unbelievable improvement it is to use the patient's own biology, not an off-the-shelf product.

Here is the original post:
Regenerative medicine will be mainstream in 10 years, says spine CEO - Becker's ASC Review

James Ankrum, a University of Iowa biomedical engineering professor, will bring his expertise in cell biology to a world-renowned research lab in Dublin.

A University of Iowa professor will travel to Ireland for a collaborative effort aimed at advancing research in the field of regenerative medicine.

James Ankrum, UI associate professor of biomedical engineering, was one of over 400 professionals, artists, and scholars who received the competitive Fulbright Scholar Award to fund his journey.

He said his work with the Royal College of Surgeons in Ireland will be an ongoing effort that combines its renowned tissue engineering program with his cell biology expertise to tailor the cells of the body for ailment therapy and relief.

This isnt just a six-month [thing], where we work together for a semester, Ankrum said. The plan is that were going to lay the foundation for a collaborative project that will last for years to come. Thats really the goal is to put in the work so that weve got a great base foundation.

Ankrums trip, he said, looks to research replicating the bodys natural signals to help those with chronic wounds.

Chronic wounds are often seen in individuals with diabetes, as well as military personnel, who are facing increasingly complex injuries from big explosions.

If we can learn how the cells in the body communicate with each other to heal rather than scar, Ankrum said. We can actually mimic those properties, those signals, those communication tactics and employ them as medicines.

Ankrums research with his Irish colleagues will continue to further their research as well.

He said the Royal College of Surgeons combines gene therapies with biomaterial scaffolding, the surface where cells are encouraged to grow.

The scaffolding has gene therapies embedded in the scaffolding and when cells migrate onto the surface of that scaffolding, the cells begin to receive the signals to reproduce.

Ankrums research allows larger-scale research into how to maximize the therapeutic aspect of the structure, Ankrum said.

The ultimate goal of research on regenerative medicine, Ankrum said, is to help reverse the effects of disease and restore the functionality of tissues that have devolved.

With heart disease, for example, tissues become diseased and are failing and no longer function as they once did, Ankrum said. Can we actually turn back the clock by understanding, What are the signals and cues and necessary players to restore true function?

Kristan Worthington, member of the Member Institute for Vision Research and UI assistant professor of biomedical engineering, focuses her research on regenerative medicine within the human retina, the part of the eye responsible for sensing light.

Lots of older people experience vision loss that is, at this point, irreversible, Worthington said. That really impacts someones quality of life in a very big way.

Worthingtons latter research focus mirrors Ankrums focus in Ireland with the biometric scaffolding.

She said regenerative research is important because researchers are still far away from being able to mimic the human bodys ability to stimulate tissue.

For me, its a lifelong pursuit of understanding and being able to modulate the human body to increase quality of life and improve the experience of humans all over the world, Worthington said.

Ankrum said regenerative medicine helps target individual suffering and alleviate it.

Being able to offer [veterans] something that isnt just, Heres pain medication, but something that can actually restore their body to what it once was before they were deployed, that plays into it, Ankrum said.

Read the original:
UI professor to research collaborative regenerative medicine in Ireland - UI The Daily Iowan

MURFREESBORO, TN - (NewMediaWire) - April 15, 2022 - via QC Kinetix -- QC Kinetix (Murfreesboro) has unveiled a series of therapies designed to reduce pain, improve range of motion, and enhance the overall quality of life. Their medical team carefully engineers the biologic therapies to provide lasting relief against joint pain and musculoskeletal injuries. For patients seeking regenerative medicine to calm the throes of chronic pain, the clinic offers zero obligation consultation with a medical provider who will explain the treatment and determine the patient's eligibility.

Chronic pain patients searching for effective regenerative medical solutions in Murfreesboro, TN, will be hard-pressed to choose QC Kinetix (Murfreesboro) as their next stop. The clinic has an experienced medical team ready to give their best to help patients overcome persistent pain and its long-term effects. These natural treatment protocols target knee pain, pain due to sports injuries, elbow pain, and shoulder pain. In addition, patients with sports injuries will readily find experts ready to attend to conditions like golfer's elbow, tennis elbow, and torn rotator cuff. Immediate intervention by QC Kinetix (Murfreesboro) providers will help the patient forgo the uncomfortable knee brace and expensive surgery. It also helps to know that the clinic is top-rated in the Murfreesboro regenerative medicine circles.

The clinic is part of QC Kinetix, a premier regenerative medicine group on a mission to improve patients' overall quality of life by easing their worries about pain and musculoskeletal injuries. Patients are also visiting the QC Kinetix (Murfreesboro) clinic due to QC Kinetix's nationwide network and personalized, concierge-level services touted to be among the very best. The non-invasive treatments also promise long-lasting results, which translates to reduced pain, improved body function and enhanced quality of life. Patients booked at the pain clinic will have their condition carefully assessed before a fitting regenerative therapy plan is created to treat the chronic pain and associated symptoms.

With as many as 80 million Americans suffering from pain, the emergence of regenerative medicine is welcome news for many people. The alternative treatment to surgery has been found effective in treating and managing chronic pain and sports injuries. It works at the cellular level by sparking organic self-repair and restoration of damaged or degenerated body tissues. For patients suffering from pain due to arthritis, regenerative medicine takes away the suffering and replaces it with long-term relief. The state-of-the-art pain control clinic in Murfreesboro, TN, provides treatment with the help of highly experienced providers trusted to administer safe and efficient biologic therapies. Joint pain patients are also invited for a dose of the breakthrough treatment targeting the fingers, toes, ankles, shoulder, wrist, and other joint areas.

QC Kinetix (Murfreesboro) is fully aware of the perils of chronic pain and its net negative impact on depriving patients of the joys of enjoying an improved quality of life. The immediate effects of chronic pain are limited mobility and the inability to perform normal day-to-day activities. To ensure transformative treatment, the providers always target the root cause of the problem before applying the non-invasive treatment protocols to overcome pain and its symptoms once and for all. People who are busy or those seeking to get on with their lives will love the idea that treatment with regenerative medicine carries little to no downtime. Leading the team of providers at the QC Kinetix (Murfreesboro) clinic are Erin Bryan, PA, and Dr. Morgan Keningston, MD, who has been working in the regenerative medicine sphere for five years. She has been a primary-care outpatient physician for eight years and an in-house hospitalist at Williamson Medical Clinic for four years.

Erin Bryan, PA, is an NCCPA-certified Physician Assistant who focuses on delivering quality care to all chronic pain patients. She holds a Bachelor's Degree in Science and a minor in Psychology. The clinic's website has testimonials that show real-life experiences and sentiments of patients treated under the QC Kinetix nationwide network. A YouTube testimonial by a severe knee pain patient shows how he could not run a full half marathon but managed to return to full racing after undergoing treatment. To learn more about their Murfreesboro office, check out their website for first-hand information about the biologic therapies, medical providers, amenities, and more personal accounts of patients who have undergone treatment.

To contact the biologic therapy medical providers, call (615) 249-4024 or visit the clinic that is strategically stationed at 1747 Medical Center Parkway, Suite 110, Murfreesboro, Tennessee, 37129. The cost of treatment using regenerative medicine is revealed during the round of consultation. Their in-house providers will disclose the actual cost after determining the patient's exact treatment, as they strive to provide affordable treatment regimens. A major plus about regenerative medicine is the correspondingly low downtime or recovery time of six to nine months after the safe and effective treatment is administered.

Source: GetFeatured

Company Name: QC Kinetix (Murfreesboro)

Contact Person: Scott Hoots

Phone: (615) 249-4024

Address: 1747 Medical Center Parkway, Suite 110

City: Murfreesboro

State: TN

Postal Code: 37129

Country: US

See the rest here:
The Advanced Pain-Free Treatment as Promoted by QC Kinetix (Murfreesboro) Regenerative Medicine in Murfreesboro, Tennesee - Yahoo Finance

AUSTIN, Texas, April 12, 2022 /PRNewswire/ -- Direct Biologics, an innovative biotechnology company with a groundbreaking extracellular vesicle (EV) platform drug technology, announced that the U.S. Food and Drug Administration (FDA) has awarded their EV drug product ExoFlo with a Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. The RMAT program is designed to expedite the approval of promising regenerative medical products in the US that demonstrate clinical evidence indicating the ability to address an unmet medical need for a serious life-threatening disease or condition. Under the RMAT designation, the FDA provides intensive guidance on drug development and post-market requirements through early and frequent interactions. Additionally, an RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA).

"After intensively reviewing our preclinical data, manufacturing processes, and clinical data from our Phase II multicenter, double blinded, placebo controlled randomized clinical trial, the FDA has recognized ExoFlo as a lifesaving treatment for patients suffering from Acute Respiratory Distress Syndrome (ARDS) due to severe or critical COVID-19," said Mark Adams, Chief Executive Officer. "The additional attention, resources, and regulatory benefits provided by an RMAT designation demonstrate that the FDA views ExoFlo as a product that can significantly enhance the standard of care for the thousands still dying from ARDS every week in the US," he said.

"We are very pleased that the FDA has recognized the lifesaving potential of our platform drug technology ExoFlo. The RMAT has provided a pathway to expedite our drug development to achieve a BLA in the shortest possible time," said Joe Schmidt, President. "I am very proud of our team. Everyone has been working around the clock for years in our mission to save human lives taken by a disease that lacks treatment options, both in the US and abroad. We are grateful for the opportunity to accelerate development of ExoFlo under the RMAT designation as it leads us closer to our goal of bringing our life saving drug to patients who desperately need it."

ExoFlo is an acellular human bone marrow mesenchymal stem cell (MSC) derived extracellular vesicle (EV) product. These nanosized EVs deliver thousands of signals in the form of regulatory proteins, microRNA, and messenger RNA to cells in the body, harnessing the anti-inflammatory and regenerative properties of bone marrow MSCs without the cost, complexity and limitations of scalability associated with MSC transplantation. ExoFlo is produced using a proprietary EV platform technology by Direct Biologics, LLC.

Physicians can learn more and may request information on becoming a study site at clinicaltrials.gov. For more information on Direct Biologics and regenerative medicine, visit: https://directbiologics.com.

About Direct BiologicsDirect Biologics, LLC, is headquartered in Austin, Texas, with an R&D facility located at the University of California, and an Operations and Order Fulfillment Center located in San Antonio, Texas. Direct Biologics is a market-leading innovator and cGMP manufacturer of regenerative medical products, including a robust EV platform technology. Direct Biologics' management team holds extensive collective experience in biologics research, development, and commercialization, making the Company a leader in the evolving segment of next generation regenerative biotherapeutics. Direct Biologics has obtained and is pursuing multiple additional clinical indications for ExoFlo through the FDA's investigational new drug (IND) process. For more information visit http://www.directbiologics.com.

SOURCE Direct Biologics

Read this article:
FDA Grants Direct Biologics Regenerative Medicine Advanced Therapy (RMAT) Designation for the use of ExoFlo in COVID-19 Related ARDS - PR Newswire

If you know at least two random people, then chances are you know somebody with somedegree of hearing loss. For many of those people, its just a minor thing an annoying reason to turn the TV volume up. But for others, it candrastically impact quality of life no longer able to make out what loved ones are saying, cut off from the music and social lifethey used to enjoy, and maybe living with endless ringing and buzzing in its place.

Atherapy that could reverse hearing loss would be life-changing for millions and thats what biotechnology company Frequency Therapeutics, a spinout company from MIT, says theyve created. Not a hearing aid, not an implant, but a new drug that can give people their hearing back.

Hearing is such an important sense; it connects people to their community and cultivates a sense of identity, said Jeff Karp, Frequency Therapeutics co-founder and professor of anesthesia at Brigham and Womens Hospital, in a statement. I think the potential to restore hearing will have enormous impact on society.

So how does this potential cure for hearing loss work? Its kind of amazing: the drug stimulates progenitor cells a descendent of stem cells that live in the inner ear to start new making hair cells.

Making your ears more hirsute may not sound like the obvious cure for hearing loss, but it actually makes a lot of sense. We sometimes think of hearing as finishing when the noise hits our eardrum, but thats only half of the story: after that, the vibrations from the sound waves move on to the ossicles the three smallest bones in your body. These tiny bones are really neat: they basically act like a hammer hitting a gong thats next to a loudspeaker. Except teeny.

That loudspeaker, aka the cochlea, is where the hair cells come in. Its a hollow bone in the shape of a spiral the name actually means snail shell filled with fluid. When that fluid is moved by the vibrations from the noise, up to 15,000 hair cells in the cochlea pick it up, and theyre what finally send the signals to the auditory nerve so that we can hear the original noise.

So: no hair cells, no hearing. The problem is, those cells are very fragile they can be damaged by certain illnesses and medications, or even just too many loud noises. And once theyre gone, they dont come back.

Until now, apparently.

Some of these people [in the trials] couldnt hear for 30 years, and for the first time they said they could go into a crowded restaurant and hear what their children were saying, said co-founder and MIT Institute Professor Robert Langer. Its so meaningful to them. Obviously more needs to be done, but just the fact that you can help a small group of people is really impressive to me.

Frequency Therapeutics says theyve already given the treatment to more than 200 people, and seen significant improvements in patients hearing in three out of four clinical trials. The therapy is long-lasting hearing has been improved for nearly two years in some cases and it comes in the form of a single injection into the inner ear, making it much simpler and quicker than alternatives like gene therapy.

I wouldn't be surprised if in 10 or 15 years, because of the resources being put into this space and the incredible science being done, we can get to the point where [reversing hearing loss] would be similar to Lasik surgery, where you're in and out in an hour or two and you can completely restore your vision, Karp says. I think we'll see the same thing for hearing loss.

However,perhaps the most tantalizing aspect of this new therapy is its future potential.

Tissues throughout your body contain progenitor cells, so we see a huge range of applications, explained Frequency co-founder and Chief Scientific Officer Chris Loose. We believe this is the future of regenerative medicine.

When we were conceiving of this project, we meant for it to be a platform that could be broadly applicable to multiple tissues, added Karp.

To me its the tip of the iceberg in terms of what can be done by taking small molecules and controlling local biology.

Read the original:
Hearing Loss Can Be Reversed With New Regenerative Therapy, Say MIT Scientists - IFLScience

There are different types of cells designed for a specific job in the human body. To cite a few, white blood cells help in defence, while red blood cells carry oxygen. Stem cells are exceptional cells that possess unique regeneration abilities. They can also create more specialised kinds of cells that can replace the cells lost by the human body either through an injury or in the daily wear and tear process.

Do read: Living Cell (ASX: LCT) surges over 14% on clinical trial for Parkinson's disease

In a broader category, there are generally two types of stem cells

Advances in stem cell research have laid a strong foundation for regenerative medicine. Stem cells have become a frontier of regenerative medicine due to their unlimited self-renewal and differentiation potential.

Regenerative medicine is a division of medicine that works on rebuilding tissues or organs to resume their functions in human beings affected by several injuries or chronic diseases. It has the capability to treat complicated medical conditions that are otherwise impossible by conventional methods.

Image source: German101 | Megapixl.com

Stem cell therapy has proven its potential in treating blood disorders including leukaemia, Hodgkins disease, and non-Hodgkins lymphoma. Stem cells also hold the possibility to cure many other types of complicated medical conditions, boosting hopes for the treatment of incurable diseases.

Also read: Precision medicine: All you need to know

Stem cell research in Australia

Australian scientists have made a considerable contribution to the knowledge about stem cells found in human beings and their potential, particularly in adult stem cells.

Both private and government institutions/firms are involved in stem cell research in the nation. These efforts got a further boost when the National Stem Cell Centre was established in 2002.

Govt pours AU$25 million into stem cell research

According to a report by the Australian Department of Health, the Australian government has provided grants worth AU$25 million for enhancing Australia-led stem cell research. Starting from 2021-22, the fund will be available for over five years through two funding streams.

Stream 1 up to AU$15 million: for developing treatments based on novel stem-cell by large scale multidisciplinary teams.

Stream 2 up to AU$10 million: for large scale multidisciplinary teams. This will be directed towards examination and pre-clinical assessment of novel treatments that deploy human tissues made from stem cells.

Stem Cell Therapies Mission

The Australian government has established the Stem Cell Therapies Mission intending to develop innovative, safe, and efficient treatments to enhance the health conditions of people. It has teamed up with patients and carers and is investing an amount of AU$150 million for the mission.

Also read: How to boost your immunity and maintain distance from pathogens?

See the original post here:
What is Australian govt doing to boost stem cell research? - Kalkine Media